Clinical trials: Disease or Disorder
Neuroblastoma
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
There is currently no curative treatment for children with relapsed/refractory neuroblastoma, and for these children the 5 year survival rate is <10%. As such, new therapeutic approaches are needed to treat these children.
- Trial name
- NCT00486564
- Testing
- Nifurtimox
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease With Complications or Failure of Medical Treatment
Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease
The study aimed to prove EEN is effective for inducing early clinical remission, mucosal healing, promoting fistula closure and reducing the size of abscess to adult CD patients.
- Trial name
- NCT02887287
- Testing
- EEN
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Tick Borne Encephalitis, Lyme Disease
Tick-borne Encephalitis and Possible Borrelial Serology
In Europe, tick-borne encephalitis (TBE) virus causing TBE is transmitted by the bite of Ixodes ricinus tick, which can also transmit Lyme borreliae , the causative agent of Lyme borreliosis (LB).
- Trial name
- NCT03958058
- Testing
- Anti-borrelial antibiotic therapy, No antibiotic.
- Where
- Slovenia
- Volunteers
- 690 people
- Sponsor
- University Medical Centre Ljubljana
Apgar Score, Motor Coordination or Function; Developmental Disorder
Effect of Tobacco Use on the Health of the Newborn up to 24 Months.
There is scientific evidence suggesting that tobacco use during pregnancy is associated with several adverse effects in newborns, including low birth weight, respiratory complications, severe neonatal morbidity, perinatal death…
- Conditions
- Apgar Score, Motor Coordination or Function; Developmental Disorder, Lactation, Weight Control
- Trial name
- ETUHeNewBorn (NCT07427706)
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Coronary Artery Disease, Chronic Kidney Diseases
Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease
The IVUS-CKD study is a prospective, randomized controlled, multicenter trial to determine whether the intravascular ultrasound (IVUS)-guided percutaneous coronary intervention is superior to the angiography-guidance in chronic…
- Trial name
- IVUS-CKD (NCT06567938)
- Testing
- Percutaneous coronary intervention
- Where
- China
- Volunteers
- 1,528 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00036738
- Testing
- Cyclosporine, Dasatinib, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Recurrent or Metastatic Solid Tumors With Positive ALPP
Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors…
- Trial name
- NCT07123493
- Testing
- Anti ALPP CAR-T cells treatment
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Haifeng Qin
Relapsed or Refractory Multiple Myeloma
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
- Trial name
- NCT05913804
- Testing
- YTS104 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Solid Tumors, Metastatic Cancer
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
The aim of this research is to evaluate the potential interest of an association of Pazopanib, a multi-tyrosine kinase inhibitor, and cisplatin.
- Trial name
- PACIFIK (NCT01165385)
- Testing
- cisplatin, Pazopanib
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- UNICANCER
Macular Degeneration
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
This study will measure antibody levels in the blood of people with bleeding or swelling in the retina who have or have not been treated with bevacizumab (Avastin[Trademark]or ranibizumab (Lucentis[Trademark]).
- Trial name
- NCT00605943
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Acute Bronchitis, Chronic Bronchitis
Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), pelargonium sidoides extract 9mL(t.i.d.) or Placebo for 7 days.
- Trial name
- NCT01420445
- Testing
- YHD001 dose level 1, YHD001 dose level 2, Pelargonium sidoides extract
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Yuhan Corporation
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Stable Angina Pectoris
Quality of Life and Target Achievement After Treatment of Patients With Stable Angina Pectoris
The purpose of this study is to, in patients with stable angina pectoris, assess the additional benefit of PCI on top of optimized medical treatment, physical training and smoking cessation with regard to quality of life…
- Trial name
- LOBSTR (NCT00825604)
- Testing
- Percutaneous coronary angioplasty (PCI)
- Where
- Sweden
- Sponsor
- Göteborg University
Sphincter of Oddi Dysfunction
Virtual Reality in SOD
Patients with classic type-3 Sphincter of Oddi dysfunction have chronic debilitating pain not amenable to pharmacologic or endoscopic therapy.
- Trial name
- NCT03999333
- Testing
- Virtual Reality (Oculus Go)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Cedars-Sinai Medical Center
Solid Tumor
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator, but will not be recruiting locally.
- Trial name
- NCT01683149
- Testing
- Topotecan, Sorafenib
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Inflammatory Bowel Disease (IBD)
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients
The primary purpose of the study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy with patients not receiving immunosuppressants .
- Trial name
- MICIVAX (NCT01022749)
- Testing
- Vaccine, Vaccine anti-H1N1
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autism Spectrum Disorder, Minimally Verbal Ability
Explore the Therapeutic Effect of Theta Burst Stimulation on Emotion Regulation in Autism With Minimally Verbal Ability or Intellectual Disability
The investigator would like to investigate the impact of theta-burst stimulation over left DLPFC in autism with minimally verbal ability or intellectual disability
- Conditions
- Autism Spectrum Disorder, Minimally Verbal Ability, Intellectual Disability
- Trial name
- NCT06974838
- Testing
- intermittent theta burst stimulation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Lumbar Disc Disease
SPI-directed Analgesia for Lumbar Discectomy
The aim of this randomized trial is to assess the efficacy of analgesia for lumbar discectomy and compare Numerical Rating Scale (NRS) with Surgical Pleth Index (SPI) for monitoring pain perception postoperatively.
- Trial name
- SPI (NCT02971540)
- Testing
- Metamizol, Tramadol, Bupivacaine
- Where
- Poland
- Volunteers
- 132 people
- Sponsor
- Medical University of Silesia
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.